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Abstract: Prophylaxis against Pneumocystis jirovecii pneumonia
(PCP) is recommended for at least 4–12 months after solid organ
transplant. In our center, renal transplant recipients receive only
1 month of post-transplant trimethoprim–sulfamethoxazole, which
also may provide limited protection against Nocardia. We
identified only 4 PCP cases and 4 Nocardia cases in 1352 patients
receiving renal and renal-pancreas transplant from 2003 to 2009 at
the University of Michigan Health System. Two PCP cases were
identified <1 year after transplant, and 2 PCP cases were
identified >1 year after transplant (gross attack rate 4/1352, 0.3%).
Two Nocardia cases were identified <1 year after transplant, and 2
cases were identified >1 year after transplant. All identified cases
received induction therapy (7 of 8 with anti-thymocyte globulin),
whereas about one-half of all renal transplant patients received
induction therapy at our institution. No patient was treated for
rejection within 6 months of PCP; 2 of 4 patients with PCP had
recent cytomegalovirus infection. All patients with PCP and 3 of 4
patients with Nocardia survived. The benefits of prolonged PCP
prophylaxis should be weighed against the adverse events
associated with prolonged use of antimicrobials.
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As Pneumocystis jirovecii pneumonia (PCP) occurs in
immunocompromised hosts, including solid organ
transplant recipients (1), the current American and
European guidelines recommend PCP prophylaxis for
at least 4–12 months after renal transplant (2, 3).
Trimethoprim–sulfamethoxazole (TMP-SMX) is rec-
ommended as the first-line agent for PCP prophylaxis,
and this agent may provide some protection against
other opportunistic pathogens including Nocardia spe-
cies (4). PCP is very rare in renal transplant recipi-
ents receiving TMP-SMX prophylaxis; in one series,
no cases were observed among 534 patients while on
prophylaxis (5).
PCP rates from <1% to 41% have been observed in
renal transplant recipients before the routine use of
PCP prophylaxis (5). As most centers currently use
some form of prophylaxis to prevent PCP pneumonia,
recent data are limited regarding the rates of PCP
and Nocardia after renal transplant with modern
immunosuppressive regimens but without prophy-
laxis. A large observational study of PCP infection in
renal transplant recipients from 2000 to 2004 revealed
a cumulative incidence of 0.4%; the use of prophylaxis
in those patients was not reported (6). A recent sin-
gle-center study of Nocardia infection in organ trans-
plant patients from 1995 to 2005 determined a rate of
0.2% in renal transplant patients (7).
In our institution, renal transplant recipients
receive only 1 month of post-transplant TMP-SMX (1
single-strength tablet daily) after renal transplanta-
tion, partially for prophylaxis against urinary tract
infection. Because this brief duration of prophylaxis
is uncommon in transplant centers in the United
States (8), we sought to determine the rate of PCP
in renal transplant patients receiving very short
courses of TMP-SMX. As TMP-SMX also has activity
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against Nocardia, we also assessed rates of Nocardia
infection.
Methods
The University of Michigan Health System is a 930-
bed tertiary care medical center performing >400 solid
organ transplants annually. Cases of PCP and nocardi-
osis in renal and renal-pancreas transplants performed
from 2003 to 2009 were identified by querying the
electronic medical record of renal transplant recipi-
ents with the search terms “Pneumocystis pneumonia,”
“PCP pneumonia,” “pneumocystis,” “pneumocytosis,”
“Pneumocystis jirovecii,” “Pneumocystis carinii,” “No-
cardia,” and “nocardiosis.”
As per long-standing institutional practice, a diagno-
sis of PCP was established with a positive PCP poly-
merase chain reaction assay from a bronchoalveolar
lavage (BAL) or sputum specimen. A diagnosis of
nocardiosis was established with a positive culture
from sputum, BAL, or brain biopsy. The gross attack
rates for PCP and nocardiosis were calculated by
dividing the number of PCP or Nocardia cases by the
total number of renal and renal-pancreas transplant
recipients in the study period. In infected patients,
demographic data, immunosuppressive medications,
the receipt of induction or rejection therapy, receipt
of PCP prophylaxis including type and duration,
history of cytomegalovirus (CMV) infection, and
survival were recorded.
Standard maintenance immunosuppression con-
sisted of tacrolimus (goal trough tapered to 4–8 ng/
mL by month 3) or cyclosporine (goal trough tapered
to 150–200 ng/mL by month 3), mycophenolate mofetil
(MMF) 1 g twice daily, and prednisone (tapered to
10 mg daily by month 2). Rabbit anti-thymocyte glob-
ulin (ATG) (Thymoglobulin; Genzyme, Cambridge,
Massachusetts, USA) induction was given to patients
at high risk for rejection. Patients not receiving ATG
with delayed graft function were treated with basilix-
imab.
Results
We reviewed 1352 patients receiving renal and renal-
pancreas transplants. Four cases of PCP (gross attack
rate 4/1352, 0.3%) and 4 cases of Nocardia (gross
attack rate 4/1352, 0.3%) were identified. Two cases
of PCP occurred <1 year after transplant and 2 PCP
cases occurred >1 year after transplant (Table 1).
Two Nocardia cases occurred <1 year after transplant
and 2 cases occurred >1 year after transplant
(Table 2). Two of 4 PCP cases received TMP-SMX 1
single-strength tablet daily for 30 days after trans-
plant, 1 PCP case received TMP-SMX for 1 year as
required by a study protocol, and 1 PCP case received
1 dose of inhaled pentamidine because of sulfa
allergy. Three of 4 Nocardia cases received TMP-
SMX for 30 days after transplant, and 1 Nocardia case
received 1 dose of inhaled pentamidine.
Immunosuppressive regimens for all cases included
MMF, prednisone, and either cyclosporine or tacroli-
mus. All identified PCP and Nocardia cases received
induction immunosuppression, with 7 of 8 cases
receiving ATG, whereas approximately one-half of all
renal transplant patients received induction immuno-
suppression at our institution. No patient was treated
for rejection within 6 months before diagnosis of PCP
or Nocardia infection. Two of 4 patients with PCP
Pneumocystis jirovecii pneumonia (PCP) cases among 1352 renal and renal-pancreas transplant recipients from 2003 to 2009
Year of
transplant
PCP months
after transplant Survival Rejection Induction
Maintenance
immunosuppression Prophylaxis (comment)
2007 10 months Yes None ATG MMF, PRED, TACRO TMP-SMX 9 30 days
(CMV 2 months before PCP)
2006 10.5 months Yes None ATG MMF, PRED, CYP TMP-SMX 9 30 days
(CMV 4 months before PCP)
2004 15 months Yes None Anti-IL2Ra MMF, PRED, TACRO TMP-SMX 9 1 year (study protocol)
2006 15 months Yes Steriod
pulse 9 2
ATG MPA, PRED, TACRO IP 9 1 dose pulse 8 months before PCP
ATG, anti-thymocyte globulin; MMF, mycophenolate mofetil; PRED, prednisone; TACRO, tacrolimus; TMP-SMX, trimethoprim-sulfamethoxazole;
CMV, cytomegalovirus; CYP, cyclosporine; IL2Ra, interleukin 2 receptor alpha; MPA, mycophenolic acid; IP, inhaled pentamidine.
Table 1
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infection had recent CMV infection. All patients with
PCP and 3 of 4 patients with Nocardia survived.
Two of the 4 PCP cases presented with hypoxia.
Treatment of PCP was variable; 1 patient received
TMP-SMX, 1 patient received clindamycin and pri-
maquine owing to sulfa allergy, and 2 patients started
TMP-SMX but completed therapy with atovaquone
owing to TMP-SMX intolerance. Secondary prophy-
laxis was also variable; 1 patient received TMP-SMX 3
times per week for >4 years, 1 patient received
atovaquone daily for about 1 year, 1 patient received
dapsone 3 times per week for about 2.5 years until
immunosuppression was tapered for graft failure, and
1 patient received no secondary prophylaxis. In all
cases, MMF or mycophenolic acid was held during
treatment of infection, and in 1 case, a lower dose of
MMF was resumed after completion of PCP treat-
ment.
Discussion
In our institution, PCP is rare in renal and renal-pan-
creas transplant recipients, despite common use of
cell-depleting induction immunosuppression and only
a 1-month duration of PCP prophylaxis. Nocardia
cases are equally rare. Both PCP and Nocardia
cases were evenly distributed <12 months and
>12 months after transplant. No case occurred dur-
ing the first 4–6 months after transplant, the time
period generally considered of highest risk (2).
Three of 4 PCP cases and all Nocardia cases
received induction with ATG. No cases were treated
for rejection, although 2 PCP cases had been treated
for CMV within 6 months, which is a recognized
risk factor for PCP (9, 10).
Historically, rates of PCP pneumonia after renal
transplantation have varied from <1% to 41% (but gen-
erally around 5%) (5). As about 90% of transplant
centers employ highly effective PCP prophylaxis for
at least 3 months after transplantation (8), the
expected incidence of PCP in patients using modern
immunosuppressive regimens, but not receiving pro-
phylaxis, is unclear. A number of reports do, however,
describe a very low rate of PCP with no or incomplete
prophylaxis, similar to the low rate noted in our study
(11–15). These low rates of PCP were followed by
outbreaks of PCP leading to the use of prophylaxis
(11–15).
Two placebo-controlled trials of TMP-SMX prophy-
laxis after renal transplantation were published in the
1990s. Among 138 renal transplant recipients at the
University of Wisconsin receiving anti-lymphocyte
globulin induction randomized to TMP-SMX or pla-
cebo for 1 year, only 1 case of PCP occurred in the
placebo group (16). Conversely, a study conducted at
Massachusetts General Hospital comparing 6 months
of ciprofloxacin with TMP-SMX for prevention of uri-
nary tract infection demonstrated a 14% (7/51) rate of
PCP in the ciprofloxacin arm (17).
We identified a number of factors that might
account for the low rate of PCP observed over an
extended period of time at our center. MMF has been
demonstrated to have a protective effect against PCP
in virus-free rats given dexamethasone (18). Further-
more, 3 registration trials conducted in the 1990s of
MMF demonstrated no cases of PCP in the MMF
group and 1.2–2.4% in the comparator group (19–21).
Some patients did receive induction with ATG; receipt
of PCP prophylaxis was not uniform or well
described. The degree of protection against PCP pro-
vided by MMF is clearly limited, as many reported
cases (particularly in outbreaks) as well as the cases
in this report occurred in patients receiving MMF (6,
12). This suggests that any protective effect of MMF
is far inferior (and may not be clinically relevant) to
that provided by TMP-SMX or other commonly used
preventative agents.
Nocardia cases among 1352 renal and renal-pancreas transplant recipients from 2003 to 2009
Year of
transplant
Nocardia months
after transplant Survival Rejection Induction
Maintenance
immunosuppression Site; Nocardia species
2009 3 months No None ATG MMF, PRED, CYP CNS; N. asteroides
2003 4.5 months Yes None ATG MMF, PRED, TACRO Pulmonary; N. asteroides
2005 18.5 months Yes None ATG MMF, PRED, TACRO CNS; N. asteroides
2006 30 months Yes None ATG MPA, PRED, TACRO Pulmonary; N. farcinica
ATG, anti-thymocyte globulin; MMF, mycophenolate mofetil; PRED, prednisone; CYP, cyclosporine; CNS, central nervous system; TACRO,
tacrolimus; MPA, mycophenolic acid.
Table 2
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Recent data suggest that PCP colonization, even in
healthy adults, may be more common than previously
thought (22), leading to speculation that clinical
disease in some circumstances may be related to
reactivation of latent disease in the setting of immuno-
suppression (23). Theoretically, a brief course of
TMP-SMX prophylaxis might eradicate colonization,
resulting in a lower incidence of PCP even after with-
drawal of prophylaxis.
A number of centers have reported outbreaks of
between 10 and 27 cases of PCP among renal trans-
plant recipients after a long period of few observed
cases, despite incomplete or absent prophylaxis (11–
15). No environmental source of PCP has been identi-
fied, and PCP is not a zoonosis. Thus, interhuman
transmission is the most likely cause of these out-
breaks (23).
Local or geographic factors (low rates of PCP colo-
nization, clinic or hospital arrangement decreasing
risk of person-to-person transmission) may have
accounted for the low rate seen in our populations, as
well as varying rates seen in other studies of patients
not receiving prophylaxis.
In addition to decreasing the risk of PCP-associated
morbidity and mortality, TMP-SMX prophylaxis may
provide additional protection against opportunistic
infections like Nocardia and toxoplasmosis. Our
Nocardia rate was similar to the rate reported in a
recent single-center study of Nocardia infection,
suggesting that limiting prophylaxis to 1 month does
not increase the risk of this infection (7). We did not
specifically investigate for the occurrence of toxoplas-
mosis in our institution, but this infection is rare in
recipients of renal transplants, and universal prophy-
laxis is not recommended (24).
Conclusions
Renal transplant recipients treated with only 1 month
of TMP-SMX prophylaxis had a very low rate of
PCP, with only 4 cases occurring in 1352 patients.
This low rate was observed despite significant use of
ATG for induction of immunosuppression. The bene-
fits of PCP prophylaxis should be weighed against
the adverse events associated with prolonged use of
antimicrobials. Reports of outbreaks of PCP indicate
that centers not using prophylaxis should monitor
rates of PCP and be prepared to introduce prophy-
laxis. Furthermore, PCP prophylaxis is likely to be
needed in patients who develop other PCP risk fac-
tors (e.g., CMV infection, treatment for organ rejec-
tion).
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